Acceptance of polyamine inhibitor car-t combination abstract for online publication

Minneapolis, oct. 25, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that an abstract about sbp-101 and cpp-1x (also known as dfmo or eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the american society of hematology (ash) meeting site in the november supplemental issue of the journal blood.
PBLA Ratings Summary
PBLA Quant Ranking